K
Kaitlin M. Woo
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 78
Citations - 4352
Kaitlin M. Woo is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Lung cancer & Carcinoma. The author has an hindex of 30, co-authored 78 publications receiving 3350 citations. Previous affiliations of Kaitlin M. Woo include Cornell University & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Troy Z. Horvat,Nelly G. Adel,Thu-Oanh Dang,Parisa Momtaz,Michael A. Postow,Margaret K. Callahan,Richard D. Carvajal,Mark A. Dickson,Sandra P. D'Angelo,Kaitlin M. Woo,Katherine S. Panageas,Jedd D. Wolchok,Paul B. Chapman +12 more
TL;DR: In the experience, approximately one-third of ipilimumab-treated patients required systemic corticosteroids, and almost one- third of those required further immune suppression with anti-TNFα therapy, which does not affect OS or TTF.
Journal ArticleDOI
Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy
Jarushka Naidoo,Xuan Wang,Xuan Wang,Xuan Wang,Kaitlin M. Woo,Kaitlin M. Woo,Tunc Iyriboz,Tunc Iyriboz,Darragh Halpenny,Jane Cunningham,Jane Cunningham,Jamie E. Chaft,Jamie E. Chaft,Neil H. Segal,Neil H. Segal,Margaret K. Callahan,Margaret K. Callahan,Alexander M. Lesokhin,Alexander M. Lesokhin,Jonathan E. Rosenberg,Jonathan E. Rosenberg,Martin H. Voss,Martin H. Voss,Charles M. Rudin,Charles M. Rudin,Hira Rizvi,Hira Rizvi,Xue Hou,Xue Hou,Katherine Rodriguez,Katherine Rodriguez,Melanie Albano,Ruth Ann Gordon,Ruth Ann Gordon,Charles Leduc,Charles Leduc,N. Rekhtman,N. Rekhtman,Bianca Harris,Bianca Harris,Alexander M. Menzies,Alexander M. Menzies,Alexander D. Guminski,Matteo S. Carlino,Matteo S. Carlino,Benjamin Y. Kong,Benjamin Y. Kong,Jedd D. Wolchok,Jedd D. Wolchok,Michael A. Postow,Georgina V. Long,Matthew D. Hellmann,Matthew D. Hellmann +52 more
TL;DR: Pneumonitis associated with anti- PD-1/PD-L1 mAbs is a toxicity of variable onset and clinical, radiologic, and pathologic appearances that is more common when anti-PD-1-L 1 mAbs are combined withAnti-cytotoxic T-cell lymphocyte-4 mAb.
Journal ArticleDOI
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.
M. Catherine Pietanza,Saiama N. Waqar,Lee M. Krug,Afshin Dowlati,Christine L. Hann,Alberto Chiappori,Taofeek K. Owonikoko,Kaitlin M. Woo,Robert J. Cardnell,Junya Fujimoto,Lihong Long,Lixia Diao,Jing Wang,Yevgeniva Bensman,Brenda Hurtado,Patricia M. de Groot,Erik P. Sulman,Ignacio I. Wistuba,Alice P. Chen,Martin Fleisher,John V. Heymach,Mark G. Kris,Charles M. Rudin,Lauren Averett Byers +23 more
TL;DR: SLFN11 expression was associated with improved PFS and OS in patients receiving TMZ/veliparib, suggesting a promising biomarker of PARP-inhibitor sensitivity in SCLC.
Journal ArticleDOI
Long-term Survival Based on the Surgical Approach to Lobectomy For Clinical Stage I Nonsmall Cell Lung Cancer: Comparison of Robotic, Video-assisted Thoracic Surgery, and Thoracotomy Lobectomy.
Hao Xian Yang,Kaitlin M. Woo,Camelia S. Sima,Manjit S. Bains,Manjit S. Bains,Prasad S. Adusumilli,Prasad S. Adusumilli,James Huang,James Huang,David J. Finley,David J. Finley,Nabil P. Rizk,Nabil P. Rizk,Valerie W. Rusch,Valerie W. Rusch,David R. Jones,David R. Jones,Bernard J. Park,Bernard J. Park +18 more
TL;DR: Minimally invasive approaches to lobectomy for clinical stage I NSCLC result in similar long-term survival as thoracotomy, and use of VATS and robotics is associated with shorter length of stay, and the robotic approach resulted in greater lymph node assessment.
Journal ArticleDOI
Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma
Andreas Rimner,Marjorie G. Zauderer,Daniel R. Gomez,Prasad S. Adusumilli,Preeti K. Parhar,Abraham J. Wu,Kaitlin M. Woo,Ronglai Shen,Michelle S. Ginsberg,Ellen Yorke,David C. Rice,Anne S. Tsao,K. E. Rosenzweig,Valerie W. Rusch,Lee M. Krug +14 more
TL;DR: Hemithoracic IMPRINT for malignant pleural mesothelioma (MPM) is safe and has an acceptable rate of RP, and its incorporation with chemotherapy and P/D forms a new lung-sparing treatment paradigm for patients with locally advanced MPM.